Ophthalmology. Retina最新文献

{"title":"Malabsorption Syndromes and Risk of Age-Related Macular Degeneration","authors":"Hejin Jeong BA ,&nbsp;Priya S. Eppel MD ,&nbsp;David C. Kaelber MD, PhD ,&nbsp;Rishi P. Singh MD ,&nbsp;Katherine E. Talcott MD","doi":"10.1016/j.oret.2026.01.002","DOIUrl":"10.1016/j.oret.2026.01.002","url":null,"abstract":"<div><h3>Purpose</h3><div>Despite mechanistic links connecting malnutrition and gut microbiome with retinal health, clinical research exploring the relationship between malabsorption syndromes and age-related macular degeneration (AMD) remains limited. This study compared the risks of AMD diagnosis in patients with and without various malabsorption syndrome diagnoses.</div></div><div><h3>Design</h3><div>Retrospective cohort study of aggregated, deidentified patient data from multiple health care organizations across the United States using the TriNetX US Collaborative Research Network in November 2025.</div></div><div><h3>Participants</h3><div>Adults with a cataract-related International Classification of Diseases (ICD) encounter diagnosis codes and no baseline AMD ICD encounter diagnosis codes were divided into groups based on the presence of ICD encounter diagnosis codes for celiac disease, ulcerative colitis (UC), Crohn’s disease (CrD), chronic pancreatitis (CP), and short bowel syndrome (SBS). Within the CP cohort, patients with pancreatic enzyme replacement therapy (PERT) prescription orders were subanalyzed. For each cohort, a corresponding control cohort of patients without the respective ICD encounter diagnosis codes was created.</div></div><div><h3>Methods</h3><div>The study and control cohorts were propensity-matched 1:1 on demographic factors, comorbidities, and disease-related conditions and prescription orders. The matched cohorts were compared on the risk of having AMD ICD encounter diagnoses.</div></div><div><h3>Main Outcome Measures</h3><div>Risk ratios (RRs) and 95% confidence intervals (CIs) of having an AMD ICD encounter diagnosis code with an accompanying retinal OCT Common Procedural Terminology code. Significance was defined as CI ≤0.9 or ≥1.1.</div></div><div><h3>Results</h3><div>Compared with controls without inflammatory bowel diseases, the CrD cohort (n = 9537, RR = 1.42, CI = 1.15–1.74), but not the UC cohort (n = 15 039, RR = 1.28, CI = 1.09–1.51), had a higher risk of having early/intermediate AMD. Chronic pancreatitis was associated with an increased risk of AMD (n = 12 856, RR = 1.82, CI = 1.53–2.16), even in the PERT subset (n = 3812, RR = 1.83, CI = 1.35–2.48). Short bowel syndrome (n = 3747) was associated with an increased risk of advanced/exudative AMD (RR = 1.98, CI = 1.31–2.98), but not early/intermediate AMD (RR = 1.28, CI = 0.96–1.71). Celiac disease was not associated with increased AMD risk (n = 9315, RR = 1.09, CI = 0.88–1.35).</div></div><div><h3>Conclusions</h3><div>Chronic noninfectious causes of malabsorption syndromes—CrD, CP, and SBS—may represent underrecognized risk factors of AMD. This explorative study adds clinical evidence for a potential role of the gut–retina axis in the pathogenesis of AMD.</div></div><div><h3>Financial Disclosure(s)</h3><div>Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.</div></div>","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":"10 5","pages":"Pages 490-498"},"PeriodicalIF":5.7,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145948781","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rate of Age-Related Macular Degeneration in Patients Prescribed Glucagon-Like Peptide-1 Receptor Agonists or Other Weight Loss Therapies","authors":"Walter K. Myers BS ,&nbsp;Garrett Heath BA ,&nbsp;Bärbel Rohrer PhD","doi":"10.1016/j.oret.2025.12.016","DOIUrl":"10.1016/j.oret.2025.12.016","url":null,"abstract":"<div><h3>Purpose</h3><div>To compare the hazard of age-related macular degeneration (AMD) among nondiabetic, weight loss–eligible adults prescribed glucagon-like peptide-1 receptor agonists (GLP-1 RAs; semaglutide or liraglutide) versus other weight loss (OWL) pharmacotherapies (phentermine, orlistat, setmelanotide, phentermine–topiramate, or bupropion–naltrexone).</div></div><div><h3>Design</h3><div>Retrospective cohort study.</div></div><div><h3>Participants</h3><div>Adults aged ≥50 years without diabetes who met the criteria for weight loss pharmacotherapy and were prescribed GLP-1 RAs or OWL medications were included. Before matching, 60 336 patients were included in the GLP-1 RA group and 21 609 in the OWL cohort; after matching, 20 959 patients remained in each cohort.</div></div><div><h3>Methods</h3><div>Cohorts were constructed using de-identified data from the TriNetX Research Network (June 2021–October 2025). Nondiabetic status was defined as the absence of a diabetes mellitus diagnosis, hemoglobin A1c ≥6.5%, or metformin or insulin use. Patients met criteria for weight loss pharmacotherapy with documentation of an obesity diagnosis, body mass index (BMI) ≥30 kg/m², or BMI ≥27 kg/m² with dyslipidemia or hypertension, recorded within 1 year before initiation. Inclusion required ≥2 prescriptions for a single study medication ≥6 months apart. Patients with recorded medication cross-exposure or outcome diagnoses before index were excluded. Cohorts were matched for demographics, established AMD risk factors, covariates influencing treatment allocation, access to ophthalmic care, and proxies for social determinants of health using 1:1 propensity score matching. Outcomes were assessed using Cox proportional hazards models.</div></div><div><h3>Main Outcome Measures</h3><div>Hazard ratios (HRs) of nonexudative AMD, exudative AMD, and any AMD (exudative, nonexudative, or unspecified). Changes in BMI and hemoglobin A1c were analyzed to contextualize findings.</div></div><div><h3>Results</h3><div>Compared with OWL pharmacotherapies, GLP-1 RAs were associated with a lower hazard of nonexudative AMD (HR, 0.47; 95% confidence interval [CI], 0.28–0.78) and any AMD (HR, 0.61; 95% CI, 0.43–0.85), with no difference for exudative AMD (HR, 0.63; 95% CI, 0.30–1.32). Body mass index and hemoglobin A1c were similar over follow-up.</div></div><div><h3>Conclusions</h3><div>Among nondiabetic adults aged ≥50 years eligible for weight loss pharmacotherapy, prescriptions for GLP-1 RAs were associated with a lower incidence of nonexudative and any (nonexudative, exudative, or unspecified) AMD diagnoses compared with OWL medications. The difference in new exudative AMD diagnoses was not statistically significant.</div></div><div><h3>Financial Disclosure(s)</h3><div>Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.</div></div>","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":"10 5","pages":"Pages 471-479"},"PeriodicalIF":5.7,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145844062","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Foldable Capsular Vitreous Body in Aspergillus Endophthalmitis","authors":"Yan Zhou BS ,&nbsp;Shi Feng MD ,&nbsp;Rongping Dai MD","doi":"10.1016/j.oret.2025.07.021","DOIUrl":"10.1016/j.oret.2025.07.021","url":null,"abstract":"","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":"10 5","pages":"Page e39"},"PeriodicalIF":5.7,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145346351","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Substance Use Disorder Interventions and Ophthalmic Outcomes for Injection Drug Use–Associated Endogenous Endophthalmitis","authors":"Jared T. Sokol MD, MBA ,&nbsp;David J. Krasinski MD ,&nbsp;George N. Papaliodis MD ,&nbsp;Eugene Lambert MD ,&nbsp;Dean Eliott MD ,&nbsp;Eric D. Gaier MD, PhD","doi":"10.1016/j.oret.2026.01.004","DOIUrl":"10.1016/j.oret.2026.01.004","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Purpose&lt;/h3&gt;&lt;div&gt;Ophthalmologists who diagnose and treat injection drug use–associated endogenous endophthalmitis (IDU-EE) are on the frontlines of the ongoing opioid epidemic and can facilitate a multidisciplinary approach to the care of persons with substance use disorders (SUDs). To identify influential factors and opportunities for intervention, we examined recent SUD care and ophthalmic outcomes in the context of IDU-EE with attention to historical trends.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Design&lt;/h3&gt;&lt;div&gt;Retrospective cohort study&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Subjects&lt;/h3&gt;&lt;div&gt;Patients diagnosed with IDU-EE at a single, academic, tertiary-referral center from 2015 to 2021.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Methods&lt;/h3&gt;&lt;div&gt;The clinical features, treatment, and outcomes of SUDs and IDU-EE were analyzed.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Main Outcome Measures&lt;/h3&gt;&lt;div&gt;Addiction medicine outcomes: injection drug type, consultation by the addiction consult service (ACS), and initiation of medication(s) for opioid use disorder (MOUD). Ophthalmic outcomes: visual acuity (VA), ophthalmic intervention, ocular sequelae, and isolated organisms.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;div&gt;Sixty-two patients (65 eyes) with IDU-EE were included. Injected drugs included heroin (74.2%), cocaine (19.4%), and fentanyl (17.7%). Initial ophthalmic treatments were tap-and-inject (TAI) in 51 (78.5%) eyes and pars plana vitrectomy (PPV) with intravitreal antimicrobials in 9 (13.8%) eyes. Subsequent PPV was performed in 30 (46.2%) eyes. Intraocular cultures were positive in 34 (54.8%) eyes. Tap-and-inject was less likely to yield a positive culture (11/52) compared with PPV (26/39; &lt;em&gt;P&lt;/em&gt; &lt; 0.0001). Median VA improved from 1.30 (interquartile range [IQR]: 0.80–2.4) logarithm of the minimum angle of resolution (LogMAR) at presentation to 0.48 (IQR: 0.097–2.1) LogMAR at most recent follow-up (&lt;em&gt;P&lt;/em&gt; = 0.0003); VA improved in 43 (68.2%) eyes. Retinal detachment occurred in 15 (23.1%) eyes. Initial TAI versus PPV did not influence final VA. Reported fentanyl use significantly increased the odds of off-chart (less than or equal to counting fingers) VA outcome (odds ratio: 5.25, 95% confidence interval: 1.3–20.9, &lt;em&gt;P&lt;/em&gt; = 0.012) at the most recent follow-up. Among 54 patients who were admitted, 37 (68.5%) saw the ACS while hospitalized. All eligible patients who saw the ACS were offered a MOUD. Of these 24 patients, 13 (54.2%) accepted a new MOUD. No MOUDs were initiated for inpatients or outpatients who did not see the ACS.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusions&lt;/h3&gt;&lt;div&gt;Addiction consult services provide potentially life-saving care for patients with IDU-EE. The incidence and visual outcomes of this condition may be worsening in correlation with fentanyl use, which confers higher odds of poor visual outcomes. Initial vitrectomy may facilitate pathogen identification.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Financial Disclosure(s)&lt;/h3&gt;&lt;div&gt;Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":"10 5","pages":"Pages 543-551"},"PeriodicalIF":5.7,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145990299","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Timing of Preoperative Anti-VEGF for Vitrectomy in Proliferative Diabetic Retinopathy","authors":"Jinlian Zhan MD ,&nbsp;Gangan Sun MS,&nbsp;Haichun Li MS,&nbsp;Xiaoyan Deng BS,&nbsp;Xia Huang MS,&nbsp;Qingxiu Wu BS,&nbsp;Bingqian Liu MD, PhD,&nbsp;Lin Lu MD, PhD,&nbsp;Xiujuan Zhao MD, PhD","doi":"10.1016/j.oret.2025.12.019","DOIUrl":"10.1016/j.oret.2025.12.019","url":null,"abstract":"<div><h3>Objective</h3><div>To evaluate whether timing of preoperative anti-VEGF therapy given before vitrectomy for proliferative diabetic retinopathy (PDR) influences risks of postoperative vitreous hemorrhage (VH) and tractional retinal detachment (TRD).</div></div><div><h3>Design</h3><div>Single-center, retrospective cohort study.</div></div><div><h3>Participants</h3><div>A total of 608 eyes of 608 patients undergoing PDR vitrectomy were classified into a No-Pretreatment group (<em>n</em> = 100) or an Anti-VEGF group (<em>n</em> = 508). The Anti-VEGF group was stratified by injection-to-surgery interval: 1 to 3, 4 to 7, 8 to 14, and &gt;14 days.</div></div><div><h3>Methods</h3><div>Multivariable Cox proportional hazards models and Fine and Gray competing-risks models were used to analyze the time to first postoperative recurrence (defined as VH or TRD requiring intervention).</div></div><div><h3>Main Outcome Measures</h3><div>The incidence and independent predictors of postoperative VH and TRD.</div></div><div><h3>Results</h3><div>In this large clinical cohort, preoperative anti-VEGF preceding vitrectomy for PDR was associated with fewer postoperative VH events but did not reduce TRD risk. An injection-to-surgery interval of 4 to 7 days had the lowest overall postoperative recurrence (VH + TRD), whereas delays beyond 14 days were associated with highest risk of TRD. Visual acuity outcomes did not differ significantly with injection timing. These findings highlight the importance of considering injection timing in surgical planning.</div></div><div><h3>Conclusions</h3><div>In this large clincal cohort, the association between preoperative anti-VEGF and postoperative outcomes in PDR vitrectomy was complication-specific: the therapy was associated with fewer postoperative VH events but was not associated with reduced TRD risk. The 4 to 7-day interval after injection was associated with the lowest rate of postoperative recurrence, whereas delays beyond 14 days were associated with an increased risk of TRD. These findings highlight the importance of considering injection timing in surgical planning, while acknowledging that visual acuity outcomes did not differ significantly among groups.</div></div><div><h3><strong>Financial Disclosure(s)</strong></h3><div>The authors have no proprietary or commercial interest in any materials discussed in this article.</div></div>","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":"10 5","pages":"Pages 532-542"},"PeriodicalIF":5.7,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145878594","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Melphalan Followed by Brachytherapy for Uveal Melanoma","authors":"Gabriela Mousse de Carvalho MD,&nbsp;Mariel Souza Natividade MD,&nbsp;Rodrigo Jorge MD, PhD","doi":"10.1016/j.oret.2025.08.005","DOIUrl":"10.1016/j.oret.2025.08.005","url":null,"abstract":"","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":"10 5","pages":"Page e42"},"PeriodicalIF":5.7,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144992952","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Swept-Source OCT and OCT Angiography B-Scan Analysis of Inflammatory Retinal Vascular Changes","authors":"Yuka Mizuno MD ,&nbsp;Sunil K. Srivastava MD ,&nbsp;Sandeep Singh BSc ,&nbsp;Jon Whitney PhD ,&nbsp;Kimberly Baynes MSN, RN ,&nbsp;Peter K. Kaiser MD ,&nbsp;Careen Y. Lowder MD, PhD ,&nbsp;Phoebe Lin MD, PhD ,&nbsp;Danny A. Mammo MD ,&nbsp;Justis P. Ehlers MD ,&nbsp;Sumit Sharma MD","doi":"10.1016/j.oret.2026.01.006","DOIUrl":"10.1016/j.oret.2026.01.006","url":null,"abstract":"<div><h3>Purpose</h3><div>To describe swept-source OCT and OCT angiography (OCTA) B-scan findings in inflammatory retinal vascular changes.</div></div><div><h3>Design</h3><div>Observational cross sectional study of prospectively enrolled patients.</div></div><div><h3>Participants</h3><div>A total of 87 eyes from 50 patients with inflammatory retinal vascular changes.</div></div><div><h3>Methods</h3><div>Swept-source OCTA, which provides both structural OCT and OCTA B-scan data, and ultra-widefield fluorescein angiography were obtained on the same day or within 2 weeks. Structural OCT and OCTA B-scans corresponding to vessel points with inflammatory findings on fluorescein angiography were analyzed for vascular and perivascular structural changes. In eyes with comparable active and inactive phases, B-scan parameters were measured and their changes were compared.</div></div><div><h3>Main Outcome Measures</h3><div>Retinal thickness and elevation ratio, outer nuclear layer (ONL) thinning ratio, horizontal and vertical flow signal diameters of retinal veins and arteries, and perivascular changes.</div></div><div><h3>Results</h3><div>The mean age was 42.9 years. Hyporeflective and/or hyperreflective perivascular changes were observed around the flow signal in the active phase. The mean retinal thickness significantly decreased from 318.5 μm in the active phase to 260.3 μm in the inactive phase (<em>P</em> &lt; 0.01) for veins, and 300.5 to 247.0 μm (<em>P</em> &lt; 0.01) for arteries. The mean vertical flow signal diameter for veins decreased from 154.5 to 134.5 μm (<em>P</em> &lt; 0.01) and, for arteries, from 104.8 to 92.0 μm (<em>P</em> = 0.07). The mean horizontal flow signal diameters for veins changed from 145.0 to 130.1 μm (<em>P</em> = 0.07) and, for arteries, from 80.1 to 79.5 μm (<em>P</em> = 0.72). The mean retinal elevation ratio for veins significantly decreased from 1.15 to 1.06 (<em>P</em> &lt; 0.01) and, for arteries, 1.09 to 1.05 (<em>P</em> = 0.08). The mean ONL thinning ratio for veins was 0.74 in the active phase and 0.81 in the inactive phase (<em>P</em> &lt; 0.01), and, for arteries, 0.90 and 0.95 (<em>P</em> = 0.90), respectively.</div></div><div><h3>Conclusions</h3><div>OCT and OCTA B-scan data identified significant changes in retinal thickness, elevation ratio, ONL thinning ratio, and vertical flow signal diameter of veins between the active and inactive phases of inflamed retinal vessels. Additionally, OCT B-scan identified unique perivascular changes, suggesting its potential in identifying inflammatory activity.</div></div><div><h3>Financial Disclosure(s)</h3><div>Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.</div></div>","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":"10 5","pages":"Pages 552-561"},"PeriodicalIF":5.7,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145990283","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes of Pars Plana Vitrectomy in Inherited Retinal Degenerations","authors":"Ahmad Al-Moujahed MD, PhD ,&nbsp;Edward S. Lu MD ,&nbsp;Henry W. Zhou MD ,&nbsp;Kirill Zaslavsky MD, PhD ,&nbsp;Jason Comander MD, PhD","doi":"10.1016/j.oret.2025.12.013","DOIUrl":"10.1016/j.oret.2025.12.013","url":null,"abstract":"<div><h3>Purpose</h3><div>To describe the management and outcomes of pars plana vitrectomy (PPV) for common surgical retinal conditions, including epiretinal membrane (ERM), full-thickness macular hole (FTMH), and retinal detachment, in patients with inherited retinal degenerations (IRDs).</div></div><div><h3>Design</h3><div>Retrospective case series study.</div></div><div><h3>Subjects</h3><div>Patients with IRDs who underwent PPV between 2007 and 2024, excluding subretinal injections.</div></div><div><h3>Methods</h3><div>We reviewed patient demographics, clinical information, genetic testing, diagnostic testing, and surgical information.</div></div><div><h3>Main Outcome Measures</h3><div>Surgical outcomes and best-corrected visual acuity (BCVA).</div></div><div><h3>Results</h3><div>Twenty-six eyes from 25 patients were included. Seven patients (28%) had ERM, 10 patients (36%; 11 eyes) had FTMH, and 9 patients (36%) had other surgical indications. These included progressive bullous retinoschisis, nonclearing vitreous hemorrhage, rhegmatogenous retinal detachment, tractional retinal detachment secondary to Coats-like vasculopathy, persistent macular detachment after subretinal gene or stem cell therapy, and dislocated intraocular lens. The mean follow-up duration was 51 months (range, 3 months to 17 years). Mean age at diagnosis of the surgical condition was 48.2 ± 21.2 years (range, 4–77 years), and 16 patients (64%) were male. At diagnosis, BCVA was worse in eyes requiring surgery (mean 1.19 ± 0.87 logarithm of minimum angle of resolution [logMAR]) compared with fellow eyes (mean 0.65 ± 0.71 logMAR; <em>P</em> = 0.006). At postoperative month 3, BCVA (mean 1.16 ± 1.01 logMAR; <em>P</em> = 0.86) was similar to preoperative values. The BCVA at final follow-up (mean 1.12 ± 1.06 logMAR; <em>P</em> = 0.65) also did not differ significantly from baseline. In ERM eyes, mean central macular thickness improved significantly from 425 ± 158 µm preoperatively to 270 ± 79 µm at postoperative month 3 (<em>P</em> = 0.01). Eyes with better baseline BCVA and more intact ellipsoid zones appeared to achieve better visual outcomes. Among FTMH eyes, topical therapy did not result in hole closure. Surgical closure was achieved in 10 eyes (91%) with 1 surgery, while 1 eye (9%) required 2 procedures.</div></div><div><h3>Conclusions</h3><div>These data indicate that PPV for common retinal conditions can achieve a high single-surgery anatomic success rate. However, the visual gains achieved in eyes with an IRD are generally smaller than in otherwise healthy eyes, suggesting a conservative approach to patient selection.</div></div><div><h3>Financial Disclosure(s)</h3><div>The authors have no proprietary or commercial interest in any materials discussed in this article.</div></div>","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":"10 5","pages":"Pages 521-531"},"PeriodicalIF":5.7,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145828120","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Re: Szeto et al: Macular hole closure by internal limiting membrane flap without gas tamponade versus conventional surgery (Ophthalmology Retina. 2025;9:1034-1043)","authors":"Lorenzo Iuliano MD ,&nbsp;Daniele Veritti MD ,&nbsp;Paolo Lanzetta MD","doi":"10.1016/j.oret.2026.02.007","DOIUrl":"10.1016/j.oret.2026.02.007","url":null,"abstract":"","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":"10 5","pages":"Pages e35-e36"},"PeriodicalIF":5.7,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147317881","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fundus Depigmentation after Immunotherapy for Metastatic Uveal Melanoma","authors":"Richard Yi MD ,&nbsp;Alexandria Steggall ,&nbsp;Elaine M. Binkley MD","doi":"10.1016/j.oret.2025.08.003","DOIUrl":"10.1016/j.oret.2025.08.003","url":null,"abstract":"","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":"10 5","pages":"Page e41"},"PeriodicalIF":5.7,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144992904","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}